SCNX · Scienture Holdings, Inc. · Insider Trading

On February 20, 2026, the Compensation Committee of the Issuer's Board of Directors approved the award of these Restricted Shares as a discretionary stock bonus for performance in 2025. The Restricted Shares will be issued in three tranches of 166,666 shares on June 1, 2026, 166,667 shares on September 1, 2026, and 166,667 shares on December 1, 2026. Each tranche of Restricted Shares will vest three years following its respective issuance date.

On February 20, 2026, the Compensation Committee of the Issuer's Board of Directors approved the award of these Restricted Shares as a discretionary stock bonus for performance in 2025. The Restricted Shares will be issued in three tranches of 166,666 shares on June 1, 2026, 166,667 shares on September 1, 2026, and 166,667 shares on December 1, 2026. Each tranche of Restricted Shares will vest three years following its respective issuance date.

These Restricted Shares vest in two equal annual installments beginning on October 1, 2026.

These Restricted Shares vest in two equal annual installments beginning on October 1, 2026.

These shares of restricted Common Stock ("Restricted Shares") vest in two equal annual installments beginning on April 14, 2026.

These shares of restricted Common Stock ("Restricted Shares") vest in two equal annual installments beginning on April 14, 2026.

These shares of Common Stock were transferred by Dr. Shankar Hariharan to a designee of NVK Finance, LLC (the "Lender") as consideration for the Lender's consent to certain transactions contemplated by that certain First Amendment to Loan and Security Agreement, dated November 22, 2024, entered into by the Issuer, the Lender, Dr. Hariharan, and certain other parties thereto.

These shares of Common Stock were transferred by Srivatsav to a designee of NVK Finance, LLC (the "Lender") as consideration for the Lender's consent to certain transactions contemplated by that certain First Amendment to Loan and Security Agreement, dated November 22, 2024, entered into by the Issuer, the Lender, Dr. Mani, and certain other parties thereto.

These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.

These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.

These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.

These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.

These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.

These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.

This Form 4/A is being filed to amend the previous Form 4 filed by Mr. Ajjarapu on January 16, 2024 (the "Prior Form 4"). The purpose of this Form 4/A is to: (i) correct the number of securities acquired on or about January 5, 2024; (ii) correct the amount of securities beneficially owned by Mr. Ajjarapu as of that date; and (iii) correct Mr. Ajjarapu's form of ownership.

The shares were granted as consideration for services rendered by Mr. Ajjarapu.

These securities are owned directly by Mr. Ajjarapu.

This Form 4/A is being filed to amend the previous Form 4 filed by Mr. Patel on January 16, 2024 (the "Prior Form 4"). The purpose of this Form 4/A is to: (i) correct the number of securities acquired on or about January 5, 2024; (ii) correct the amount of securities beneficially owned by Mr. Patel as of that date; and (iii) correct Mr. Patel's form of ownership.

The shares were granted as consideration for services rendered by Mr. Patel.

These securities are owned directly by Mr. Patel.

Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/8th of such shares per quarter (on the first day of each calendar quarter), with the first vesting beginning on April 1, 2023, subject to the recipient's continued service to the Issuer. Exempt pursuant to Rule 16b-3.

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer and Chairperson of the Audit Committee. Issued under the Issuer's Amended and Restated 2019 Equity Incentive Plan.

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer and Chairperson of the Audit Committee. Issued under the Issuer's Amended and Restated 2019 Equity Incentive Plan.

The options vest at the rate of 1/2 of such options per year, on January 4, 2024 and 2025, subject to the recipient's continued service to the Issuer. Exempt pursuant to Rule 16b-3.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/2 of the shares on January 1, 2023 and April 1, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on December 31, 2022, March 31, 2023, June 30, 2023 and September 30, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Financial Officer.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on September 30, 2022, October 31, 2022, November 30, 2022 and December 31, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Financial Officer.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on September 30, 2022, October 31, 2022, November 30, 2022 and December 31, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as President and Chief Operating Officer.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on September 30, 2022, October 31, 2022, November 30, 2022 and December 31, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Executive Officer.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on the grant date, September 1, 2022, and 1/4th of such shares on each of October 1, 2022, January 1, 2023 and April 1, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on the grant date, September 1, 2022, and 1/4th of such shares on each of October 1, 2022, January 1, 2023 and April 1, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors.

The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the April 2021 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/3 of the shares on October 1, 2021 and January 1 and April 1, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors.

The shares were forfeited back to the Issuer as the reporting person's services to the Issuer ended on May 27, 2021, due to the vesting conditions pertaining to the award not having been achieved. Exempt under Rule 16b-3(e).

The shares were forfeited back to the Issuer as the reporting person discontinued service to the Issuer as of May 27, 2021, due to the vesting conditions pertaining to the award not having been achieved. Exempt under Rule 16b-3(e).

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/3 of the shares on October 1, 2021 and January 1 and April 1, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors.

This transaction involved a bona fide gift of securities by the Reporting Person to family and/or a friend.

This transaction involved a bona fide gift of securities by the Reporting Person to family and/or a friend.

The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the April 2021 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3.

Represents the weighted sales price for all sales made on April 19, 2021, which were made in a range of between $4.30 and $4.77 per share. The Reporting Person will provide to the Commission, the Issuer or any stockholder, upon request, full information regarding the number of shares sold at each separate price.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on July 1 and October 1, 2021 and January 1 and April 1, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors.

The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the April 2021 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3.

This transaction was executed in multiple trades at prices ranging from $4.63 to $4.77, with the price reported above reflecting the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was affected.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on July 1 and October 1, 2021 and January 1 and April 1, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on July 1 and October 1, 2021 and January 1 and April 1, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors.

The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the December 2020 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3.

Represents the weighted sales price for all sales made on December 14, 2020, which were made in a range of between $5.22 and $5.30 per share. The Reporting Person will provide to the Commission, the Issuer or any stockholder, upon request, full information regarding the number of shares sold at each separate price.

The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the December 2020 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3.

The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the December 2020 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3.

This Amended Form 4 is being filed to update the Reporting Person's beneficial ownership to include 981 shares of common stock which were inadvertently left out of the original filing.

The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the December 2020 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3.

Represents the weighted sales price for all sales made on December 14, 2020, which were made in a range of between $5.22 and $5.34 per share. The Reporting Person will provide to the Commission, the Issuer or any stockholder, upon request, full information regarding the number of shares sold at each separate price.

The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person to satisfy the Reporting Person's tax liability in connection with the April 2020 grant of certain restricted stock which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3(b).

Represents the weighted sales price for all sales made on July 14, 2020, which were made in a range of between ($5.31) and ($5.55) per share. The Reporting Person will provide to the Commission, the Issuer or any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person to satisfy the Reporting Person's tax liability in connection with the April 2020 grant of certain restricted stock which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3(b).

In April 2018, Mr. Ajjarapu, through an entity which he owned, entered into an agreement with a third party to purchase certain shares of common stock of Nexgen Memantine, Inc. ("Nexgen"). The purchase price for the shares was $1.5 million, which amount was due prior to December 31, 2019. In order to secure the payment of the purchase price, Mr. Ajjarapu provided the seller a security interest in, and pledged into escrow, 212,500 of his shares of the Issuer's common stock. Mr. Ajjarapu retained all voting and other rights associated with the pledged stock.

The purchase agreement provided that if the purchase price was not paid on December 31, 2019, an amount of Mr. Ajjarapu's shares equal in value to $1.5 million, based on 30-day average stock prices, would be transferred to the seller to satisfy the $1.5 million obligation. The purchase price was not paid on December 31, 2019, and Mr. Ajjarapu, effective on June 12, 2020, transferred 201,613 shares of the Issuer's common stock to the seller, based on a 30-day average stock price of $7.44, to satisfy the stock purchase obligation.

Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on July 1 and October 1, 2020 and January 1 and April 1, 2021, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors.

Shares are fully earned as of April 14, 2020. The table above includes the full amount of such shares which are fully earned by the Reporting Person as of April 14, 2020, even though such shares have not been issued as of the date of this filing.

Issued to the Reporting Person as a compensation bonus for 2019. Exempt under Rule 16b-3(d).